Mr George Tetley
Position: PhD student
Personal home page:
PubMed journal articles - click here
My research as part of the Owen-Mott lab is in designing a small peptide therapeutic for Ras driven cancers. Abberant Ras signalling in cells can be disrupted by inhibition of downstream effectors, one of which is Cdc42. We are basing this peptide on a specific Cdc42 effector protein - ACK - and aiming to improve binding and delivery in order to inhibit effector signalling. I am working in collaboration with Isogenica, whose CIS display technology allows rapid peptide affinity maturation. Lead candidates will be taken forward to in vitro assays.
Symplectic Elements feed provided by Research Information, University of Cambridge